Duyuru • 2h
Darwin AG announces Annual dividend, payable on July 01, 2026 Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Duyuru • May 22
Darwin AG, Annual General Meeting, Jun 26, 2026 Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time. New Risk • May 15
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 7.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin). Reported Earnings • May 15
Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024) Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Valuation Update With 7 Day Price Move • Mar 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €7.90, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year. Duyuru • Feb 26
Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026 Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026 New Risk • Feb 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 36x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past year. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €9.45, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 56% over the past year. New Risk • Jan 23
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). New Risk • Dec 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$91.3m). Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to €7.90, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year. New Risk • Sep 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€70.2m market cap, or US$82.7m). New Risk • Aug 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €87.6m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€87.6m market cap, or US$100.0m). Upcoming Dividend • Jun 23
Upcoming dividend of €2.25 per share Eligible shareholders must have bought the stock before 30 June 2025. Payment date: 02 July 2025. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.2%). New Risk • Aug 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.2m). Duyuru • May 14
Darwin AG, Annual General Meeting, Jun 18, 2024 Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.